These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 36841031)

  • 81. Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade.
    Bommareddy PK; Rabkin SD; Kaufman HL
    Oncoimmunology; 2019; 8(4):e1571390. PubMed ID: 30906668
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors.
    Yan T; Yu L; Shangguan D; Li W; Liu N; Chen Y; Fu Y; Tang J; Liao D
    Int Immunopharmacol; 2023 Feb; 115():109638. PubMed ID: 36587500
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors.
    Yan Y; Zhang L; Zuo Y; Qian H; Liu C
    Arch Immunol Ther Exp (Warsz); 2020 Nov; 68(6):36. PubMed ID: 33185750
    [TBL] [Abstract][Full Text] [Related]  

  • 84. The Era of Checkpoint Inhibition: Lessons Learned from Melanoma.
    Paschen A; Schadendorf D
    Recent Results Cancer Res; 2020; 214():169-187. PubMed ID: 31473853
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC).
    Chae YK; Arya A; Iams W; Cruz MR; Chandra S; Choi J; Giles F
    J Immunother Cancer; 2018 May; 6(1):39. PubMed ID: 29769148
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.
    Harrington KJ; Puzanov I; Hecht JR; Hodi FS; Szabo Z; Murugappan S; Kaufman HL
    Expert Rev Anticancer Ther; 2015; 15(12):1389-403. PubMed ID: 26558498
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Review of the recent clinical trials for PD-1/PD-L1 based lung cancer immunotherapy.
    Behrouzieh S; Sheida F; Rezaei N
    Expert Rev Anticancer Ther; 2021 Dec; 21(12):1355-1370. PubMed ID: 34686070
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Modulating the Tumor Microenvironment via Oncolytic Viruses and CSF-1R Inhibition Synergistically Enhances Anti-PD-1 Immunotherapy.
    Shi G; Yang Q; Zhang Y; Jiang Q; Lin Y; Yang S; Wang H; Cheng L; Zhang X; Li Y; Wang Q; Liu Y; Wang Q; Zhang H; Su X; Dai L; Liu L; Zhang S; Li J; Li Z; Yang Y; Yu D; Wei Y; Deng H
    Mol Ther; 2019 Jan; 27(1):244-260. PubMed ID: 30527756
    [TBL] [Abstract][Full Text] [Related]  

  • 89. PD-1/PD-L1 immune checkpoint blockade in ovarian cancer: Dilemmas and opportunities.
    Peng Z; Li M; Li H; Gao Q
    Drug Discov Today; 2023 Aug; 28(8):103666. PubMed ID: 37302543
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Oncolytic virus and PD-1/PD-L1 blockade combination therapy.
    Chen CY; Hutzen B; Wedekind MF; Cripe TP
    Oncolytic Virother; 2018; 7():65-77. PubMed ID: 30105219
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Reverse Translating Molecular Determinants of Anti-Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models.
    Georgiev P; Muise ES; Linn DE; Hinton MC; Wang Y; Cai M; Cadzow L; Wilson DC; Sukumar S; Caniga M; Chen L; Xiao H; Yearley JH; Sriram V; Nebozhyn M; Sathe M; Blumenschein WM; Kerr KS; Hirsch HA; Javaid S; Olow AK; Moy LY; Chiang DY; Loboda A; Cristescu R; Sadekova S; Long BJ; McClanahan TK; Pinheiro EM
    Mol Cancer Ther; 2022 Mar; 21(3):427-439. PubMed ID: 34965960
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1.
    Cervera-Carrascon V; Quixabeira DCA; Santos JM; Havunen R; Milenova I; Verhoeff J; Heiniö C; Zafar S; Garcia-Vallejo JJ; van Beusechem VW; de Gruijl TD; Kalervo A; Sorsa S; Kanerva A; Hemminki A
    Front Immunol; 2021; 12():706517. PubMed ID: 34367166
    [TBL] [Abstract][Full Text] [Related]  

  • 93. CD4
    Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
    [TBL] [Abstract][Full Text] [Related]  

  • 94. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
    Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
    Front Immunol; 2021; 12():654463. PubMed ID: 34054817
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Oncolytic herpes simplex virus HF10 (canerpaturev) promotes accumulation of CD8
    Eissa IR; Mukoyama N; Abdelmoneim M; Naoe Y; Matsumura S; Bustos-Villalobos I; Ichinose T; Miyajima N; Morimoto D; Tanaka M; Fujimoto Y; Sone M; Kodera Y; Kasuya H
    Int J Cancer; 2021 Jul; 149(1):214-227. PubMed ID: 33687756
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials.
    Chu X; Tian W; Wang Z; Zhang J; Zhou R
    Mol Cancer; 2023 Jun; 22(1):93. PubMed ID: 37291608
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials.
    Huang Z; Zheng S; Ding S; Wei Y; Chen C; Liu X; Li H; Xia Y
    J Cancer Res Ther; 2021 Jul; 17(3):676-687. PubMed ID: 34269299
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy.
    Constantinidou A; Alifieris C; Trafalis DT
    Pharmacol Ther; 2019 Feb; 194():84-106. PubMed ID: 30268773
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Enhanced Anti-Tumor Response Elicited by a Novel Oncolytic Pseudorabies Virus Engineered with a PD-L1 Inhibitor.
    Xiang G; Wang M; Wang P; Li R; Gao C; Li Y; Liang X; Liu Y; Xu A; Tang J
    Viruses; 2024 Jul; 16(8):. PubMed ID: 39205202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.